Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Goebell

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
Future Oncology (London, England)|February 14, 2024
Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and AsiaPeter J Goebell, Rutika Raina, Stephanie Chen, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 19, 2017
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder CancerQi Pan, Anuja Sathe, Peter C Black, et al.
International Journal of Cancer|September 10, 2019
Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-RegistryMichael Staehler, Peter J Goebell, Lothar Müller, et al.
Aktuelle Urologie|June 4, 2025
[Androgen receptor-targeted therapies - avoid clinically relevant interactions]Hans-Peter Lipp, Gunhild von Amsberg, Axel S Merseburger, et al.
Urology|January 10, 2006
Low-grade Ta (noninvasive) urothelial carcinoma of the bladderWillem Oosterlinck, Eduardo Solsona, Hideyuki Akaza, et al.
Urologic Oncology|August 23, 2018
Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-RegistryPeter J Goebell, Lothar Müller, Andreas Hübner, et al.
Journal of Clinical Medicine|May 30, 2019
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell CarcinomaAndreas Kahlmeyer, Christine G Stöhr, Arndt Hartmann, et al.
Urologie (Heidelberg, Germany)|August 20, 2025
[Update guideline on prostate cancer-balancing act between evidence and healthcare reality]Axel Belusa, Peter J Goebell, Peter Kollenbach, et al.
Oncology Research and Treatment|January 19, 2022
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)Viktor Grünwald, Thomas Hilser, Johannes Meiler, et al.
Anticancer Research|October 25, 2017
Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational StudyHendrik Heers, Patrick DE Geeter, Peter J Goebell, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Future Oncology (London, England)|February 14, 2024
Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and AsiaPeter J Goebell, Rutika Raina, Stephanie Chen, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 19, 2017
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder CancerQi Pan, Anuja Sathe, Peter C Black, et al.
International Journal of Cancer|September 10, 2019
Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-RegistryMichael Staehler, Peter J Goebell, Lothar Müller, et al.
Aktuelle Urologie|June 4, 2025
[Androgen receptor-targeted therapies - avoid clinically relevant interactions]Hans-Peter Lipp, Gunhild von Amsberg, Axel S Merseburger, et al.
Urology|January 10, 2006
Low-grade Ta (noninvasive) urothelial carcinoma of the bladderWillem Oosterlinck, Eduardo Solsona, Hideyuki Akaza, et al.
Urologic Oncology|August 23, 2018
Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-RegistryPeter J Goebell, Lothar Müller, Andreas Hübner, et al.
Journal of Clinical Medicine|May 30, 2019
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell CarcinomaAndreas Kahlmeyer, Christine G Stöhr, Arndt Hartmann, et al.
Urologie (Heidelberg, Germany)|August 20, 2025
[Update guideline on prostate cancer-balancing act between evidence and healthcare reality]Axel Belusa, Peter J Goebell, Peter Kollenbach, et al.
Oncology Research and Treatment|January 19, 2022
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)Viktor Grünwald, Thomas Hilser, Johannes Meiler, et al.
Anticancer Research|October 25, 2017
Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational StudyHendrik Heers, Patrick DE Geeter, Peter J Goebell, et al.
Pageof 11